Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis

Journal of the National Cancer Institute

Volumn 106, Issue 7, 2014, Pages

  Guan, Bin ^a,d   Suryo Rahmanto, Yohan ^a   Wu, Ren Chin ^a,b   Wang, Yihong ^a   Wang, Zhong ^c   Wang, Tian Li ^a   Shih, Ie Ming ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARID1A GENE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM HYPERPLASIA; EPITHELIUM; FEMALE; GENE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PTEN GENE; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA;

ANIMALS; CARCINOMA; CARCINOMA, ENDOMETRIOID; CODON, NONSENSE; DNA-BINDING PROTEINS; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE KNOCKOUT TECHNIQUES; GENES, TUMOR SUPPRESSOR; MICE; MICE, KNOCKOUT; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84905224527     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju146     Document Type: Article

References (27)

1. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228-231.
2. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532-1543.
3. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Human Mut. 2012;33(1):100-103.
4. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35(5):625-632.
5. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
6. Guan B, Wang TL, Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNFmediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718-6727.
7. Mamo A, Cavallone L, Tuzmen S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 2012;31(16):2090-2100.
8. Wang DD, Chen YB, Pan K, et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One. 2012;7(7):e40364.
9. Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and noninfection-related bile duct cancers. Nat Gen. 2013;45(12):1474-1478.
10. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gyn Cancer. 2012;22(8):1310-1315.
11. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Archiv.2012;460(1):77-87.
12. Mao TL, Ardighieri L, Ayhan A, et al. Loss of ARID1A Expression Correlates With Stages of Tumor Progression in Uterine Endometrioid Carcinoma. Am J Surg Pathol. 2013;37(9):1342-1348.
13. Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nature Gen. 2013;45(6):592-601.
14. McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014;27(1):128-134.
15. Groszer M, Erickson R, Scripture-Adams DD, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001;294(5549):2186-2189.
16. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11(4):321-333.
17. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11(1):63-70.
18. Flesken-Nikitin A, Choi KC, Eng JP, et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 2003;63(13):3459-3463.
19. Szabova L, Yin C, Bupp S, et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 2012;72(16):4141-4153.
20. Kinross KM, Montgomery KG, Kleinschmidt M, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest. 2012;122(2):553-557.
21. Seidman JD, Cho K, Ronnett BM, et al. Surface epithelial tumors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, eds. Blaustein's Pathology of the Female Genital Tract. 6th e.d.
22. Altrabulsi B, Malpica A, Deavers MT, et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29(10):1316-1321.
23. Silva EG, Deavers MT, Bodurka DC, et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: A new type of dedifferentiated carcinoma? Int J Gyn Pathol. 2006;25(1):52-58.
24. Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Modern Pathol. 2010;23(6):781-789.
25. Wu ES, Shih IM, Diaz-Montes TP. Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor? Gynecol Oncol Case Rept. 2013;5:25-27.
26. Kuhn E, Ayhan A, Bahadirli-Talbott A, et al. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol. 2014;38(5):660-665.
27. Blanco-Aparicio C, Renner O, Leal JF, et al. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28(7):1379-1386